Image

Global Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Prescription Digital Therapeutics (PDTx) Market, By Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults) – Industry Trends and Forecast to 2029

Prescription Digital Therapeutics (PDTx) Market

Market Analysis and Size                              

Prescription digital therapies are a unique strategy that allows software implementations to quickly treat major diseases. It is designed to deliver evidence-based treatment everywhere and at any time and give physicians real-time data on patient progress. Prescription digital therapeutics have been developed and are in the development stage for a variety of diseases, including substance use disorder (SUD), opioid use disorder (OUD), ADHD, major depressive disorder (MDD), insomnia, multiple sclerosis, oncology, migraine, epilepsy, autism spectrum disorder, and cardiovascular disease. Patients with various unmet requirements may find prescription digital therapies to be the most crucial aspect of their lives.

Data Bridge Market Research analyses that the Global prescription digital therapeutics (PDTx) market was valued at USD 3.239 billion in 2021 and is expected to reach USD 14.21 billion by 2029, registering a CAGR of 20.30% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults),

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), GAIA AG (Germany), Welldoc’s Bluestar (U.S.),Solera Network (U.S.), Akili Interactive Labs, Inc. (U.S.), Better Therapeutics, LLC (U.S.), BigHealth (U.S.), Biofourmis (U.S.),Click Therapeutics, Inc. (U.S.), Happify, Inc. (U.S.), Limbix Health, Inc. (U.S.), Naturalcycles Nordic AB (Sweden), NuvoAir AB (Sweden), Sensyne Health plc. (U.K.), Xealth (U.S.)

Market Opportunities

 

  • Increase in the number of research and development activities
  • Strong pipeline of potential products

Market Definition

Prescription digital therapies is a type of software that is used to treat a variety of ailments. Prescription digital medicines were created by combining biology and technology. Artificial intelligence, diverse algorithms, and virtual reality are used to develop these therapeutic instruments. Patients might use prescription digital therapeutics software and services to get any form of treatment whenever and wherever they needed it. Prescription digital treatments have gained a lot of popularity since they are tightly regulated by the FDA and other regulatory authorities and can only be used with a proper prescription from a doctor.

Global Prescription Digital Therapeutics (PDTx) Market Dynamics

Drivers

  • Rise in the prevalence of chronic diseases

The surging prevalence of chronic diseases is a major factor driving the prescription digital therapeutics (PDTx) market's growth rate during the forecast period of 2022-2029. As per the World Health Organization (WHO), 463 million adults would have diabetes in 2020. According to predictions, there would be roughly 629 million diabetics worldwide by 2045.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of prescription digital therapeutics (PDTx) market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising adoption rate of smartphones and tablets will expand the prescription digital therapeutics (PDTx) market. Additionally, increasing government initiatives for better healthcare services and surging the geriatric population will expand prescription digital therapeutics (PDTx) market. Along with this, easy accessibility, patient comfort, and the potentiality to influence behavioural change will enhance the market's growth rate.

Opportunities

  • Strong pipeline of potential products

A significant pipeline of potential items projected to be released throughout the forecast period will provide beneficial opportunities for the prescription digital therapeutics (PDTx) market growth. Pear-011 (anxiety GAD), Pear-015 (depression MDD), which are used in the treatment of adults with chronic insomnia and depression, and CT-152 (major depressive disorder), CT-155 (schizophrenia), which are used in the treatment of adults with schizophrenia and depression, are illustrations of potential pear therapeutics clinical therapeutics products in phase III. As a result, various late-stage drugs in the pipeline are anticipated to give attractive prospects for the digital therapeutics market to flourish.

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the biologics market growth. Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of prescription digital therapeutics (PDTx) during the forecast period.

Restraints/Challenges

On the other hand, patient data privacy concerns will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the prescription digital therapeutics (PDTx) market. Additionally, strict government regulations and lack of awareness about digital therapeutics in developing countries will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Prescription digital therapeutics (PDTx) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Global Prescription Digital Therapeutics (PDTx) Market

COVID-19 has a positive general influence on the prescription digital therapeutics (PDTx) sector. Due to increased global awareness of the relevance of digital health, the prevalence of mental illness, and the rate of drug usage. Furthermore, because individuals were forced to stay at home during the pandemic, less physical exercise, an unhealthy lifestyle, and mental stress increased the prevalence of chronic diseases. As a result, demand for prescription digital therapeutics (PDTx) devices and software is increasing around the world. The industry is expected to increase further since regulatory clearances for prescription digital therapeutics (PDTx)-based treatments have recently been eased.

In the middle of the COVID-19 outbreak, the US FDA issued provisional advice for Pear Therapeutics' mental health medications. It also implies that regulatory agencies recognize the significance of digital therapeutics goods. In addition, digital health businesses in the United States raised USD 5.4 billion in venture capital in the first half of 2020, a record high in the history of digital health funding, indicating that investors believe these solutions are necessary. Hence, the COVID-19 pandemic is predicted to boost the market for prescription digital therapeutics (PDTx).

Global Prescription Digital Therapeutics (PDTx) Market Scope

The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application and patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mechanism

  • Input Mechanisms
  • Output Mechanisms

Category

  • Medication Augmentation
  • Medication Replacement

Treatment

  • Outpatient Treatment
  • Monotherapy

Software

  • Software for Respiratory Conditions
  • Software for Mental Health
  • Software for Opioid Use Disorder
  • Software for Diabetes
  • Others

Services

  • Behavioral Microservices
  • Medical Microservices

App Accessibility

  • Android
  • iOS
  • Windows

App Type

  • Native Apps
  • Web Apps

Application

  • Substance Use Disorder (SUD)
  • Opioid Use Disorder (OUD)
  • Attention Deficit/Hyperactivity Disorder (ADHD)
  • Alzheimer’s Disease
  • Major Depressive Disorder (MDD)
  • Insomnia
  • Epilepsy
  • Movement Disorder
  • Multiple Sclerosis
  • Migraine
  • Autism Spectrum Disorder
  • Oncology
  • Inflammation
  • Respiratory
  • Cardiovascular
  • Pain Management
  • Metabolic Conditions
  • Others

Patients

  • Children
  • Adults

Global Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights

The prescription digital therapeutics (PDTx) market is analysed and market size insights and trends are provided by country, mechanism, category, treatment, software, services, app accessibility, app type, application and patients as referenced above.

The countries covered in the prescription digital therapeutics (PDTx) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the prescription digital therapeutics (PDTx) market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rise in the research and development going on the prescription digital therapeutics (PDTx) and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players and the influx of new start-ups will further propel the market’s growth rate in this region.

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to rising healthcare expenditure and the increasing prevalence of chronic diseases in this region. Also, advancements in the reimbursement structure for the digital therapeutics will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Prescription Digital Therapeutics (PDTx) Market Share Analysis

The prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prescription digital therapeutics (PDTx) market.

Some of the major players operating in the prescription digital therapeutics (PDTx) market are:

  • ResMed (U.S.)
  • SAMSUNGHEALTHCARE (South Korea)
  • Biofourmis (US)
  • Novartis AG (Switzerland)
  • Medtronic (Ireland)
  • Pear Therapeutics, Inc. (U.S.)
  • Voluntis (France)
  • Omada Health, Inc. (U.S.)
  • GAIA AG (Germany)
  • Welldoc’s Bluestar (U.S.)
  • Solera Network (U.S.)
  • Akili Interactive Labs, Inc. (U.S.)
  • Better Therapeutics, LLC (U.S.)
  • BigHealth (U.S.)
  • Biofourmis (U.S.)
  • Click Therapeutics, Inc. (U.S.)
  • Happify, Inc. (U.S.)
  • Limbix Health, Inc. (U.S.)
  • Naturalcycles Nordic AB (Sweden)
  • NuvoAir AB (Sweden)
  • Sensyne Health plc. (U.K.)
  • Xealth (U.S.)


SKU-

Why Choose Us


Frequently Asked Questions

The Market Value for Prescription Digital Therapeutics (Pdtx) Market is expected USD 14.21 billion by 2029.
The Expansion of the Global Prescription Digital Therapeutics (Pdtx) Market will be fueled by a continuous surge in the chronic diseases worldwide and cost effectiveness of prescription digital therapeutics (PDTx) will further cushion the market’s growth rate during the forecast period.
The Major Companies Operating in the Prescription Digital Therapeutics (Pdtx) Market are Pear Therapeutics, Inc. (U.S.), Akili Interactive Labs, Inc. (Boston), Welldoc’s BlueStar (U.S.), Voluntis (France), GAIA AG (Italy), BigHealth (U.S.), Happify, Inc (U.S.)., NaturalCycles (Sweden) and Nordic AB (Sweden).
The Countries Covered in the Prescription Digital Therapeutics (Pdtx) Market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.